Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the Company's website at http://www.pharmion.com.
Rhonda Chiger Donald F. Corcoran
Rx Communications Group, LLC President & CEO
Phone: 917-322-2569 MethylGene Inc.
email@example.com Phone: 514-337-3333 ext. 373
Breanna Burkart Anna Sussman
Director, Investor Relations Director, Investor Relations
and Corporate Communications and Corporate Communications
Phone: 720-564-9144 Phone: 720-564-9143
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995: This release contains forward-looking statements relating to
the planned development program for MGCD0103, which express the current
beliefs and expectations of management. Such statements are based on
current expectations and involve a number of known and unknown risks and
uncertainties that could cause Pharmion's future results, performanc
|SOURCE Pharmion Corporation|
Copyright©2007 PR Newswire.
All rights reserved